Literature DB >> 22151003

Combined effect of 25-OH vitamin D plasma levels and genetic vitamin D receptor (NR 1I1) variants on fibrosis progression rate in HCV patients.

Katharina Baur1, Joachim C Mertens, Johannes Schmitt, Rika Iwata, Bruno Stieger, Jyrki J Eloranta, Pascal Frei, Felix Stickel, Michael T Dill, Burkhardt Seifert, Heike A Bischoff Ferrari, Arnold von Eckardstein, Pierre-Yves Bochud, Beat Müllhaupt, Andreas Geier.   

Abstract

BACKGROUND: Decreased vitamin D levels have been described in various forms of chronic liver disease and associated with advanced fibrosis. Whether this association is a cause or consequence of advanced fibrosis remains unclear to date. AIMS: To analyse combined effects of 25-OH vitamin D plasma levels and vitamin D receptor gene (VDR; NR1I1) polymorphisms on fibrosis progression rate in HCV patients.
METHODS: 251 HCV patients underwent VDR genotyping (bat-haplotype: BsmI rs1544410 C, ApaI rs7975232 A and TaqI rs731236 A). Plasma 25-OH vitamin D levels were quantified in a subgroup of 97 patients without advanced fibrosis. The VDR haplotype and genotypes as well as plasma 25-OH vitamin D levels were associated with fibrosis progression.
RESULTS: The bAt[CCA]-haplotype was significantly associated with fibrosis progression >0.101 U/year (P = 0.007; OR = 2.02) and with cirrhosis (P = 0.022; OR = 1.84). Forty-five percent of bAt[CCA]-haplotype patients were rapid fibrosers, 21.1% were cirrhotic. Likewise, ApaI rs7975232 CC genotype was significantly associated with fibrosis progression and cirrhosis. Lower plasma 25-OH vitamin D levels were significantly associated with fibrosis progression >0.101 U/year in F0-2 patients (P = 0.013). Combined analysis of both variables revealed a highly significant additive effect on fibrosis progression with 45.5% rapid fibrosers for bAt[CCA]-haplotype and 25-OH vitamin D < 20 μg/L compared with only 9.1% for the most favourable combination (P = 0.006). In multivariate analysis, the bAt-haplotype was an independent risk factor for fibrosis progression (P = 0.001; OR = 2.83).
CONCLUSION: Low 25-OH vitamin D plasma levels and the unfavourable VDR bAt[CCA]-haplotype are associated with rapid fibrosis progression in chronic HCV patients. In combination, both variables exert significant additive effects on fibrosis progression.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22151003     DOI: 10.1111/j.1478-3231.2011.02674.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  34 in total

1.  25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients.

Authors:  Arthur Belle; Emmanuel Gizard; Guillaume Conroy; Anthony Lopez; Magali Bouvier-Alias; Stéphanie Rouanet; Laurent Peyrin-Biroulet; Jean-Michel Pawlotsky; Jean-Pierre Bronowicki
Journal:  United European Gastroenterol J       Date:  2016-07-07       Impact factor: 4.623

Review 2.  Association between vitamin D and hepatitis C virus infection: a meta-analysis.

Authors:  Livia Melo Villar; José Antonio Del Campo; Isidora Ranchal; Elisabeth Lampe; Manuel Romero-Gomez
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

3.  Could vitamin d supplementation benefit patients with chronic liver disease?

Authors:  Ilaria Barchetta
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-11

4.  Impact of FokI (rs10735810) and BsmI (rs1544410) on Treatment of Chronic HCV Patients With Genotype 4.

Authors:  Olfat Shaker; Yasser Nassar; Shymaa Ayoub; Maissa Elrazki; Amr Zahra
Journal:  J Clin Lab Anal       Date:  2016-04-18       Impact factor: 2.352

Review 5.  Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin.

Authors:  Bassem Refaat; Adel Galal El-Shemi; Ahmed Ashshi; Esam Azhar
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 6.  Association between serum vitamin D and severity of liver fibrosis in chronic hepatitis C patients: a systematic meta-analysis.

Authors:  Yue-qiu Luo; Xiao-xing Wu; Zong-xin Ling; Yi-wen Cheng; Li Yuan; Charlie Xiang
Journal:  J Zhejiang Univ Sci B       Date:  2014-10       Impact factor: 3.066

7.  Role of genetic polymorphisms in hepatitis C virus chronic infection.

Authors:  Nicola Coppola; Mariantonietta Pisaturo; Caterina Sagnelli; Lorenzo Onorato; Evangelista Sagnelli
Journal:  World J Clin Cases       Date:  2015-09-16       Impact factor: 1.337

8.  The association between serological and dietary vitamin D levels and hepatitis C-related liver disease risk differs in African American and white males.

Authors:  D L White; S Tavakoli-Tabasi; F Kanwal; D J Ramsey; A Hashmi; J Kuzniarek; P Patel; J Francis; H B El-Serag
Journal:  Aliment Pharmacol Ther       Date:  2013-05-26       Impact factor: 8.171

9.  Liver Injury Impaired 25-Hydroxylation of Vitamin D Suppresses Intestinal Paneth Cell defensins, leading to Gut Dysbiosis and Liver Fibrogenesis.

Authors:  Pengfei Wu; Ruofei Zhang; Mei Luo; Tianci Zhang; Lisha Pan; Siya Xu; Liwei Pan; Feng Ren; Cheng Ji; Richard Hu; Mazen Noureddin; Stephen J Pandol; Yuan-Ping Han
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-10-21       Impact factor: 4.052

10.  In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use.

Authors:  Andrea D Branch; Minhee Kang; Kimberly Hollabaugh; Christina M Wyatt; Raymond T Chung; Marshall J Glesby
Journal:  Am J Clin Nutr       Date:  2013-06-05       Impact factor: 7.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.